73 results about "HER2 Antibody" patented technology

Belongs to the field of biological medicine, and relates to application of an anti-HER2 antibody drug conjugate to treatment of HER2 negative breast cancer. The invention also relates to application of the anti-HER2 antibody drug conjugate in preparation of a drug for treating HER2 negative breast cancer of a subject. The invention also relates to a method for treating HER2-negative breast cancer in a subject. The method comprises the step of administering the anti-HER2 antibody drug conjugate to the subject. The method is beneficial to HER2 negative breast cancer subjects, and has good safety.

The present application provides antibodies comprising an antigen-binding fragment of an anti-CD3 antibody having tailor-made affinity to CD3 in low to medium range. In some embodiments, the antibody further comprises an antigen-binding fragment that specifically binds to a target antigen, such as HER2, CD20, TROP2, BCMA, or CD19. Also provided are anti-CD3 antibodies, masked anti-CD3 antibodies (including activatable anti-CD3 antibodies), anti-CD20 antibodies, and masked anti-HER2 antibodies (including activatable anti-HER2 antibodies). The antibodies described herein are useful for treatment of cancer.

The present application describes uses for Pertuzumab, a first-in-class HER2 dimerization inhibitor. In particular, the application describes methods for extending progression free survival in a HER2-positive breast cancer patient population; and combining two HER2 antibodies to treat HER2-positive cancer without increasing cardiac toxicity.

The invention provides a simple and rapid preparation method of a novel HER2 targeted nano-drug maytansine (DM1). The preparation of the nano-drug is realized by using carboxyl on a side chain of azide-terminated poly (L-glutamic acid) (PLG) as a load binding site. The preparation method comprises the following steps: firstly, grafting N-(2-aminoethyl) maleimide hydrochloride (Mal-C2H4-NH2-HCL) to carboxyl of PLG (Poly L-Glycol), and introducing a maleimide group to form PLG-Mal; the preparation method comprises the following steps: preparing Fc-III-4C peptide-PLG-Mal (Fc-PLG-Mal) by virtue of an amidation reaction between carboxyl and amino of the Fc-III-4C peptide, and then carrying out thiol-maleimide click chemical reaction on a maleimide group and sulfydryl of DM1, so as to obtain the Fc-PLG-DM1. Finally, the HER2 antibody and the Fc-PLG-DM1 are mixed in water by utilizing the high affinity effect between the Fc-III-4C peptide and the Fc segment of the HER2 antibody, so that the HER2-PLG-DM1 can be obtained, and the HER2-PLG-DM1 has a remarkable tumor inhibition effect in animal experiments. The successful development of the HER2-PLG-DM1 proves the potential of the method in the design and development of functional nano-drugs in the future.

The present application relates to the technical field of antibodies, in particular to HER2 antibodies or antigen-binding fragments thereof. The present application provides HER2 antibodies or antigen-binding fragments thereof, wherein the heavy chain comprises at least one mutation: CDR1 is mutated to T5M in the wild-type fragment of SEQ ID NO. 1, D6G mutation, or CDR2 is mutated to G7V in the wild-type fragment of SEQ ID NO. 2. The antibody has high affinity to HER2 S310F / Y The mutant target has the recognition ability and maintains the functional activity to the wild-type HER2.

A pharmaceutical product for administration of an anti HER2 antibody-drug conjugate in combination with an ATR inhibitor is provided. The anti-HER2 antibody-drug conjugate is an antibody-drug conjugate in which a drug linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an anti-HER2 antibody via a thioether bond. Also provided is a therapeutic use and method wherein the antibody-drug conjugate and the ATR inhibitor are administered in combination to a subject: Formula (I):

Disclosed are new anti-HER2 ADCs conjugated to camptothecin derivatives as toxins for therapeutic use. The antitumor effects of the ADCs of Formula (PL-A) (e.g., compounds MB-2a and MB-3a (trastuzumab meditecan)) render these compounds useful for treating cell proliferative diseases such as cancers.

Disclosed are new anti-HER2 ADCs conjugated to camptothecin derivatives as toxins for therapeutic use. The antitumor effects of the ADCs of Formula (PL-A) (e.g., compounds MB-2a and MB-3a (trastuzumab meditecan)) render these compounds useful for treating cell proliferative diseases such as cancers.

The application belongs to the field of biology and relates to a nucleic acid molecule encoding an anti-HER2 antibody, a vector containing the nucleic acid molecule and an expression method, wherein the nucleic acid molecule contains codons optimized for expression cells. By using the nucleic acid molecule of the application, the expression amount of the anti-HER2 antibody in cells can be improved, the yield of the anti-HER2 antibody is increased, and the production cost is reduced; and the anti-HER2 antibody produced has similar performance to that of the original research drug and has a good drug-making prospect.

The invention provides a preparation method of HER2 targeted composite nanoparticles conjugated with a blood vessel disrupting agent, which comprises the following steps: grafting water-soluble azide-terminated poly (L-glutamic acid) with methoxy polyethylene glycol (NPLG-g-mPEG) to increase the number of effective load binding sites, bonding a cytotoxic drug SN38 with NPLG-g-mPEG through Steglich esterification reaction to obtain N3-PLG-SN38, and then adding the N3-PLG-SN38 into the HER2 targeted composite nanoparticles conjugated with the blood vessel disrupting agent to obtain the HER2 targeted composite nanoparticles conjugated with the blood vessel disrupting agent. According to the present invention, the Fc-PLG-SN38 is obtained by carrying out click chemical bonding on the Fc-III-4C peptide and the N3-PLG-SN38, by using the high affinity between the Fc-III-4C peptide and the Fc of the HER2 antibody, the antibody and the Fc-NPLG-SN38 are mixed in the water environment so as to obtain the HER2-PLG-SN38, and the HER2-PLG-SN38 and the blood vessel disrupting agent CA4P are conjugated so as to enhance the penetrating power and the drug effect on tumor cells;

The present disclosure pertains to the field of biomedicines and relates to use of an anti-HER2 antibody-drug conjugate in the treatment of biliary tract cancer. The present disclosure also relates to use of an anti-HER2 antibody-drug conjugate in the preparation of a medicament for treating biliary tract cancer in a subject. The present disclosure also relates to a method for treating biliary tract cancer in a subject, the method comprising administering an anti-HER2 antibody-drug conjugate to the subject. The method provides benefits for subjects with biliary tract cancer and has good safety.

This disclosure pertains to the field of biomedicine and relates to the use of an anti-HER2 antibody-drug conjugate (ADC) for the treatment of breast cancer. It also relates to a method for treating a subject with breast cancer, the method comprising administering an anti-HER2 antibody-drug conjugate to the subject. Furthermore, it relates to the use of the anti-HER2 antibody-drug conjugate in the preparation of a medicament for neoadjuvant therapy of breast cancer. The method provides benefit to breast cancer subjects and has a good safety profile.

The application belongs to the field of biological medicine, and relates to the use of an anti-HER2 antibody drug conjugate for treating breast cancer. The application also relates to the use of an anti-HER2 antibody drug conjugate in the preparation of a medicament for treating breast cancer in a subject. The application also relates to a method for treating breast cancer in a subject, which comprises administering an anti-HER2 antibody drug conjugate to the subject. The method is beneficial to the breast cancer subject, and has good safety.

Provided are a humanized / fully human HER2 antibody or an antigen-binding fragment thereof, and an antibody-radionuclide conjugate using same as a targeting group for radioactive labeling, showing a tumor-targeting enrichment ability.

The present invention belongs to the field of biology, and relates to a nucleic acid molecule encoding an anti-HER2 antibody, a vector comprising the nucleic acid molecule, and an expression method wherein the nucleic acid molecule comprises codons optimized for expression cells. By utilizing the nucleic acid molecule disclosed by the invention, the expression quantity of the anti-HER2 antibody in cells can be increased, the yield of the anti-HER2 antibody is increased, and the production cost is reduced; and the produced anti-HER2 antibody is similar to an original research drug in performance and has a relatively good patent medicine prospect.

A pharmaceutical composition characterized in that a combination of an (anti-HER2 antibody)-drug conjugate and a HER dimerization inhibitor is administered, in which the (anti-HER2 antibody)-drug conjugate comprises a drug linker represented by the formula shown below (wherein A represents a binding position to an anti-HER2 antibody) and an anti-HER2 antibody bonded to each other through a thioether bond; and / or a treatment method characterized in that a combination of the (anti-HER2 antibody)-drug conjugate and the HER dimerization inhibitor is administered to an individual.

A pharmaceutical product for administration of an anti- HER2 antibody-drug conjugate (ADC) in combination with an anti-TROP2 ADC is provided. The anti-HER2 ADC and the anti-TROP2 ADC comprise a drug-linker. An exatecan may be the drug of the drug-linker and the drug-linker may be conjugated to the respective antibody via a thioether bond. Also provided is a therapeutic use and method in which the anti-HER2 ADC and the anti-TROP2 ADC are administered in combination to a subject. The anti-HER2 ADC and anti-TROP2 ADC in combination have excellent anti-cancer properties.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

The invention provides an anti-HER2 antibody or an antigen binding fragment thereof, an anti-HER2 complementary bispecific antibody and a complementary bispecific antibody-drug conjugate (ADC) constructed by the anti-HER2 antibody or the antigen binding fragment, and a pharmaceutical composition and a kit containing the anti-HER2 antibody or the antigen binding fragment. Also provided are methods of using the antibodies, ADCs, pharmaceutical compositions and kits for treating diseases associated with abnormal expression of HER2.

Provided herein are methods for treating cancer or preventing the progression of cancer in a subject, the methods comprising administering to the subject an effective amount of an anti-PD-1 antibody, such as a tereprenicmab, and an anti-HER2 antibody-drug conjugate comprising an anti-human epidermal growth factor receptor 2 (HER2) antibody and a cytotoxic molecule. Compositions, uses, and kits related thereto are also provided.

To provide uses of pertuzumab, which is a first in-class HER2 dimerization inhibitors, and articles of manufacture comprising the same.SOLUTION: A method for extending progression free survival in a population of HER2 + breast carcinoma patients; a method for combining two HER2 antibodies to treat HER2 + breast carcinoma without increasing cardiotoxicity; a method for treating early HER2 + breast carcinoma; a method for treating HER2 + breast carcinoma by co-administering a mixture of pertuzumab and trastuzumab from the same I. v. bag; a method for treating HER2 + metastatic gastric carcinoma; a method for treating HER2 + breast carcinoma with pertuzumab, trastuzumab and vinorelbine; Methods for treating HER2 positive breast cancers with trastuzumab and aromatase inhibitors; and methods for treating low HER3 ovarian, primary peritoneal, or fallopian tube cancers are provided.SELECTED DRAWING: None

Provided are methods of treating cancer (e.g., non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), HER2-positive gastric / gastroesophageal junction (GEJ) cancer, de novo or transformed diffuse large B cell lymphoma (DLBCL), or indolent lymphoma) in an individual that comprise administering to the individual (a) a polypeptide comprising a SIRPα D1 domain variant and an Fc domain variant, and (b) an anti-cancer antibody (e.g., an anti-PD1 antibody, anti-HER2 antibody, or an anti-CD20 antibody). Also provided are related kits pharmaceutical compositions.

[Problem] To provide a novel combination therapy for a disease, particularly cancer. [Solution] The present invention provides the administration of an anti-HER2 antibody-drug conjugate in combination with an additional agent, such as an immune checkpoint inhibitor.

The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.

The present invention relates to stable liquid pharmaceutical formulations containing a high concentration of trastuzumab, pertuzumab or a mixture thereof for convenient subcutaneous administration. Formulations of the present invention can be administered to treat cancer, such as breast cancer and metastatic gastric or gastroesophageal junction adenocarcinoma.

The invention provides immunoconjugates of Formula I comprising an anti-HER2 antibody linked by conjugation to one or more 8-Het-2-aminobenzazepine derivatives. The invention also provides 8-Het-2-aminobenzazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.

Disclosed herein are anti-HER2 antibodies and antigen-binding fragments, chimeric antigen receptors ("CARs") having these anti-HER2 antibodies and antigen-binding fragments ("HER2 CARs") and genetically modified immune effector cells having such HER2 CARs. Polynucleotides encoding the anti-HER2 antibodies and antigen-binding fragments and HER2 CARs are also provided herein. Compositions comprising anti-HER2 antibodies and antigen-binding fragments and HER2 CARs are also provided herein. The present disclosure also provides use of the anti-HER2 antibodies and antigen-binding fragments and genetically modified immune effector cells having such HER2 CARs in cancer treatment.

Provided herein are methods for treating or preventing progression of cervical cancer in an individual, including administering to the individual an effective amount of an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that comprises an anti-HER2 antibody and a cytotoxic molecule. Also provided herein are methods for treating or preventing progression of cervical cancer in an individual, including administering to the individual an effective amount of an anti-HER2 antibody-drug conjugate that includes an anti-HER2 antibody and a cytotoxic molecule, in combination with an anti-PD-1 antibody. Also provided herein are uses of an anti-HER2 antibody-drug conjugate, or an anti-HER2 antibody drug conjugate in combination with an anti-PD-1 antibody, for manufacture of a medicament for treating or preventing progression of a previously treated cervical cancer in an individual. Also provided herein are pharmaceutical compositions for use in treating a previously treated cervical cancer in an individual.

The present invention relates to the use of a HER2 antibody directed against an epitope between amino acids 342-652 of human HER2 in combination with a second HER2 inhibitor for the treatment of a HER2-related disorder. More specifically, the present invention relates to methods and uses of MAB270 or an antibody having the same CDRs as MAB270 in combination with trastuzumab or pertuzumab in a HER2-positive cancer.